生血宁片辅助治疗急性髓系白血病患者贫血的疗效  

Efficacy of Shengxuening tablets in the adjuvant treatment of anemia in patients with acute myeloid leukemia

作　　者：唐萍 方佳敏 周怡[1] 王倩 周芙玲[1] 胡晓梅[2] TANG Ping;FANG Jiamin;ZHOU Yi;WANG Qian;ZHOU Fuling;HU Xiaomei(Dept.of Hematology,Zhongnan Hospital of Wuhan University,Wuhan 430071,Hubei,China;Xiyuan Hospital of China Academy of Chinese Medical Science,Beijing 100091,China)

机构地区：[1]武汉大学中南医院血液内科,湖北武汉430071 [2]中国中医科学院西苑医院,北京100091

出　　处：《武汉大学学报（医学版）》2023年第9期1093-1097,共5页Medical Journal of Wuhan University

基　　金：国家自然科学基金资助项目(编号:81900116);武汉大学中南医院学科与平台建设基金(编号:PDJH202217)。

摘　　要：目的:观察生血宁片对急性髓系白血病(AML)患者贫血的临床改善情况。方法:收集2019—2023年诊断为AML伴有贫血的住院患者107例,随机分为对照组(51例)和观察组(56例),两组患者均使用重组人促红细胞生成素(EPO)治疗,后者在EPO的基础上加用生血宁片,对两组患者治疗前后的临床疗效、血常规、铁代谢以及炎症指标进行统计分析。结果:观察组总有效率(81.5%)明显高于对照组(57.4%)(P=0.008);观察组患者经生血宁片治疗后的红细胞(RBC)、血红蛋白(HGB)、血小板(PLT)、红细胞压积(HCT)以及平均红细胞体积(MCV)与观察组治疗前和对照组治疗后相比,均有明显升高(P<0.05);观察组治疗后的铁蛋白(SF)水平较治疗前和对照组治疗后有改善(P<0.05);炎症指标上的比较,白细胞介素⁃6(IL⁃6)和C反应蛋白(CRP)在生血宁片治疗后均有明显下降(P<0.05)。结论:生血宁片不仅有效治疗AML患者的贫血,并在一定程度上降低高铁蛋白和炎症因子,具备积极的临床应用价值。Objective:To observe the effect of Shengxuening tablets on anemia in patients with acute my⁃eloid leukemia(AML).Methods:A total of 107 patients diagnosed with AML and anemia admitted from 2019 to 2023 were involved and randomly divided into control group(51 cases)and observation group(56 cases).Both groups were treated with recombinant human erythropoietin(EPO),and the lat⁃ter were treated with Shengxuening tablets on the basis of EPO.The clinical efficacy,complete blood cell count(CBC),iron metabolism and inflammatory indexes of the two groups before and after treat⁃ment were statistically analyzed.Results:The total effective rate of the observation group(81.5%)was significantly higher than that of the control group(57.4%)(P=0.008);in terms of CBC,the red blood cell(RBC),hemoglobin(HGB),platelet(PLT),hematocrit(HCT),and mean corpuscular vol⁃ume(MCV)of the observation group after treatment were significantly higher than those of the obser⁃vation group before treatment and of the control group after treatment(P<0.05);the serum ferritin(SF)level of the observation group after treatment was improved as compared with that before treat⁃ment and that of the control group after treatment(P<0.05);the levels of interleukin⁃6(IL⁃6)and C⁃re⁃active protein(CRP)were significantly decreased after Shengxuening tablets treatment(P<0.05).Conclusion:Shengxuening tablets not only effectively treat anemia in AML patients,but also relieve the high levels of serum ferritin and inflammatory factors to a certain extent,which has positive clinical application value.

关 键 词：生血宁 急性髓系白血病 贫血 铁蛋白 炎症因子 

分 类 号：R733.71[医药卫生—肿瘤]